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Background: Mesenchymal stem cells (MSC) are multipotent progenitor cells localized in the stromal compartment
of the bone marrow (BM). The potential of MSC for mesenchymal differentiation has been well documented in
different animal models predominantly on rodents. However, information regarding bovine MSC (bMSC) is limited,
and the differentiation potential of bMSC derived from fetal BM remains unknown. In the present study we sought
to isolate bMSC from abattoir-derived fetal BM and to characterize the multipotent and differentiation potential
under osteogenic, chondrogenic and adipogenic conditions by quantitative and qualitative analyses.
Results: Plastic-adherent bMSC isolated from fetal BM maintained a fibroblast-like morphology under monolayer
culture conditions. These cells expressed high levels of MSC surface markers (CD73, CD90, and CD105) and low
levels of hematopoietic surface markers (CD34 and CD45). Culture of bMSC under osteogenic conditions during a
27-day period induced up-regulation of the osteocalcin (OC) gene expression and alkaline phosphatase (ALPL)
activity, and promoted mineralization of the matrix. Increasing supplementation levels of ascorbic acid to culture
media enhanced osteogenic differentiation of bMSC; whereas, reduction of FBS supplementation compromised
osteogenesis. bMSC increased expression of cartilage-specific genes aggrecan (ACAN), collagen 2A1 (COL2A1) and
SRY (sex-determining region Y) box 9 (SOX9) at Day 21 of chondrogenic differentiation. Treatment of bMSC with
adipogenic factors increased levels of fatty acid-binding protein 2 (AP2) mRNA and accumulation of lipid vacuoles
after 18 days of culture. NANOG mRNA levels in differentiating bMSC were not affected during adipogenic culture;
however, osteogenic and chondrogenic conditions induced higher and lower levels, respectively.
Conclusions: Our analyses revealed the potential multilineage differentiation of bMSC isolated from abattoir-
derived fetal BM. NANOG mRNA pattern in differentiating bMSC varied according to differentiation culture
conditions. The osteogenic differentiation of bMSC was affected by ascorbic acid and FBS concentrations in culture
media. The simplicity of isolation and the differentiation potential suggest that bMSC from abattoir-derived fetal BM
are appropriate candidate for investigating MSC biology and for eventual applications for regenerative therapy.
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Mesenchymal stem cells (MSC) are multipotent progeni-
tor cells that localize in the stromal compartment of the
bone marrow (BM), where they support hematopoiesis
and differentiate into mesenchymal lineages [1]. The po-
tential of MSC to form bone, cartilage, and adipose tissues
has been well documented both in vivo [2] and in vitro
[3]. However, the plasticity of MSC is not limited to mes-
enchymal derivatives, since MSC have been induced to
differentiate into mesodermal, neuroectodermal and endo-
dermal lineages [1]. MSC can be directly isolated from
bone marrow aspirates based on their ability to adhere to
plastic when plated in monolayer culture, by flow cytome-
try and sorting separation or with micromagnetic beads
by using specific antibodies for stem cells [4]. Thereafter,
human multipotent stem cells derived from marrow
stroma proliferate ex vivo to form a phenotypically homo-
geneous population of cells that express surface antigens
markers CD73 (ecto-5′-nucleotidase), CD90 (Thy-1),
CD105 (endoglin) and lack expression of CD45 (protein
tyrosine phosphatase, receptor type, C), CD34 (CD34 mol-
ecule) and CD14 (CD14 molecule) [5].
The regulatory mechanisms which are essential for
maintenance of MSC characteristics or triggering differ-
entiation are only partially understood [6]. After in vitro
differentiation of human MSC into the osteogenic lineage,
evaluation of the osteocyte phenotype has identified cells
positive for the bone extracellular matrix protein osteo-
calcin (OC) and the mineralization-associated enzyme al-
kaline phosphatase (ALPL) [3,7]. Similarly, induction of
chondrogenic differentiation results in the majority of cells
expressing cartilage-specific proteins including matrix
markers aggrecan (ACAN) and collagen 2A1 (COL2A1),
and essential transcription factor SRY (sex-determining
region Y) box 9 (SOX9) [8]. Whereas, the adipogenic in-
duction has been characterized in human and mouse
MSC by increase in the expression of fatty acid peroxi-
some proliferation-activated receptor γ (PPARγ) and fatty
acid-binding protein 2 (AP2) [3,9].
Several studies have evaluated the expression of dif-
ferentiation markers in MSC linages; however, fewer re-
ports have analyzed the expression of pluripotent genes
during differentiation of MSC. The transcriptional regula-
tor octamer-binding protein 4 (OCT4) along with co-
regulators NANOG and SRY (sex-determining region Y)
2 (SOX2) coordinate a program of gene activity that sup-
presses differentiation and allows self-renewal in embry-
onic stem (ES) cells [10,11]. In MSC; however, levels of
OCT4 are low [12] or inexistent [13] and its activity has
been reported to be dispensable for MSC self-renewal
[12]. While the role of NANOG in MSC has been investi-
gated at lesser extent than OCT4, expression of NANOG
has been detected in MSC, where ectopic overexpression
increases the potential for osteogenic differentiation [14].Cells with features of mesenchymal precursors have
been isolated from the BM of many mammals, including
laboratory rodents [2], humans [3], cats [15], dogs [16]
and pigs [17]. Despite the wide relevance of the bovine ex-
perimental model in both in vivo and in vitro experiments,
limited information regarding bovine MSC (bMSC) is
available. Considering their similarities in organ size and
physiology with humans and their longer life span in com-
parison with the traditional laboratory animal models,
large animals are considered to be an excellent model for
long-term experiments in regenerative medicine [18,19].
Thus, derivation of bESC would be invaluable for testing
the efficiency and safety of these cells for future cell ther-
apies and for the creation of human disease models. Cattle
can give numerous advantages for making progress in
clinical applications of MSC to human medicine, espe-
cially in musculoskeletal health problems [20-22]. Previous
studies reported isolation and mesenchymal differentiation
of bMSC from calf BM [22,23] and bovine umbilical cord
[24,25]. However, differentiation potential of bMSC de-
rived from other sources including fetal BM remains un-
known. Human MSC isolated from fetal BM have been
shown to have higher proliferative capacity, trilineage dif-
ferentiation potential and lower immunogenicity com-
pared to MSC from umbilical cord, adult BM or adipose
tissue [26]. In particular, human fetal BM MSC had
higher proliferative and osteogenic capacity than MSC
derived from other ontological and anatomical origins,
suggesting they are superior candidates for bone tissue
engineering [27,28].
The development of large animal experimental models
including cattle may open alternative strategies for investi-
gating MSC physiology and eventual applications for re-
generative therapy in human and veterinary medicine.
Currently, animal BM is the most common source of
MSC for clinical and research uses. In the present study,
we used abattoir-derived bovine fetuses as an available
and plentiful source of BM with the aim to obtain an
abundant supply of bMSC and to minimize risk for donor
and recipient. Our main objective was to isolate bMSC
from abattoir-derived fetal BM and to characterize the
multipotent and differentiation potential during in vitro
osteogenic, chondrogenic and adipogenic differentiation
by quantitative and qualitative analyses.
Results
Isolation of bone marrow MSC from abattoir-derived
bovine fetuses
Isolation of bMSC from fetal BM was performed
based on the capacity for plastic attachment under
standard culture conditions that included DMEM
media supplemented with 10% FBS. Colonies of
fibroblast-like cells attached to the plastic were visu-
alized at Days 5–6 after seeding. Cells exhibited
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Isolated cells were cultured for several weeks in monolayer
and used for differentiation experiments after 4 to 5
passages.Mesenchymal cell surface markers and population
doublings
Three independent cultures of bMSC were analyzed for
the expression of mesenchymal and hematopoietic sur-
face markers using quantitative-PCR (Q-PCR). bMSC
expressed higher (P < 0.05) levels of MSC cell surface
markers CD73, CD90, CD 105 (151.2-, 245.1-, 238.1-
fold relative to CD34) compared to hematopoietic
markers CD34 and CD45 (1- and 9-fold relative to CD34;
Figure 1A). No significant differences were detected for
population doublings (PD) between consecutive passages
until passage 7 (Figure 1B).
Osteogenic differentiation
Supplementation of osteogenic factors during a 27-day
period induced cell morphology changes that included
formation of cell projections and development of intri-
cate cell interactions and extracellular matrix (Figure 2A).
OC mRNA levels significantly increased in differentiated
bMSC at Day 16 of culture (10.2-fold relative to Day 0
vs. 2.4-fold in the untreated controls) and continue to
rise through Day 27 (75.4-fold relative to Day 0 vs. 0.84-
fold in the untreated controls, Figure 2B). At Day 27,
NANOG mRNA levels significantly increased in differen-
tiated bMSC compared to Day-16 control (2.2-fold vs.
0.2-fold relative to Day 0). CD73 expression was up-
regulated (P < 0.05) in untreated control bMSC at Day 24
of culture (Figure 2C). ALPL activity increased (P < 0.05)
in differentiated bMSC at Day 27 of culture compared to
untreated controls (0.58 vs. 0.23 Abs 415 nm, Figure 2D).
OC expression was detected by immunofluorescence in
differentiated bMSC at Day 27 of culture (Figure 2E). At
this stage, an intense matrix mineralization was detected
using von Kossa staining in differentiated bMSC cultures
(Figure 2F).
Effect of ascorbic acid and FBS supplementation on bMSC
osteogenic differentiation
Supplementation of 0.1 mM of ascorbic acid to bMSC cul-
tures induced higher (P < 0.05) OC mRNA levels (102.1-
fold relative to Day 0) compared to 0.01 mM (22.9-fold)
and 0.001 mM (0.1-fold) concentrations at Day 27 of cul-
ture (Figure 3A). Reduction in FBS supplementation to 2%
resulted in lower (P < 0.05) OC mRNA (17-fold relative to
Day 0) compared to 10% (102.1-fold) and 5% (60.5-fold).
NANOG mRNA levels decreased (P < 0.05) in bMSC
supplemented with 0.1 mM (0.7-fold), 0.01 mM (1.9-fold)
and 0.001 mM (0.2-fold) of ascorbic acid compared tountreated control cells (8.7-fold). Addition of 0.1 or 0.01
mM of ascorbic acid induced higher (P < 0.05) ALPL ac-
tivity in bMSC compared to addition of 0.001 mM or no
addition of ascorbic acid (Figure 3B). Treatment of 0.1
mM of ascorbic acid in combination with 10% or 5% FBS
resulted in stronger von Kossa staining compared to other
treatments (Figure 3C).
Chondrogenic differentiation
Cultured of bMSC under chondrogenic conditions using
a micromass culture system for 21 days induced cartilage
formation (Figure 4A). Glycosaminoglycan was detected
using alcian blue staining in cartilage pellets at Day 21 of
culture (Figure 4A). ACAN mRNA levels increased signifi-
cantly in differentiated bMSC at Day 7 (29.8-fold relative
to Day 0 vs. 0.9-fold in untreated control) and continued
to rise through Day 21 of culture (89.2-fold relative to Day
0 vs. 3.5-fold in untreated control, Figure 4B). NANOG
mRNA levels were lower (P < 0.05) in differentiating
bMSC at Day 7 (5.1-fold relative to Day 0 vs. 13.7-fold in
untreated control) and at Day 21 of culture (9.2-fold rela-
tive to Day 0 vs. 24.2-fold for untreated control, Figure 4B).
COL2A1 mRNA levels increased (P < 0.05) in differenti-
ated bMSC at Day 21 of culture (14.9-fold relative to Day
0 vs. 4.1-fold in untreated control, Figure 4C). Similarly,
SOX9 mRNA levels significantly increased in differenti-
ated bMSC at Day 21 of culture (19.2-fold relative to Day
0 vs. 8.5-fold in untreated control, Figure 4D). Immunore-
activity for ACAN was detected in histological sections of
cartilage pellets at Day 21 of culture (Figure 4E).
Adipogenic differentiation
Culture of bMSC under adipogenic conditions induced
formation of cell aggregates and presence of lipid vacu-
oles in the cell cytoplasm (Figure 5A). AP2 mRNA levels
increased (P < 0.05) in differentiated bMSC at Day 12
(16.4-fold relative to Day 0 vs. 2.2-fold in untreated con-
trol) and at Day 18 (17- fold relative to Day 0 vs. 5.2-fold
in untreated control) of culture (Figure 5B). No signifi-
cant differences were detected in NANOG or PPARγ
mRNA levels between treatments or sampling days
(Figures 5B,C). PPARγ was immunodetected associated
to the nuclear cell compartment in differentiated bMSC
at day 18 of culture (Figure 5D). Moreover, lipid vacu-
oles were stained with oil red in differentiated bMSC at
Day 18 of culture (Figure 5E).
Discussion
In the present study, bMSC were isolated from BM col-
lected from abattoir-derived fetuses based on the cap-
acity to adhere to plastic flasks under monolayer culture
conditions. This method has been reported for isolation
of MSC in various animal models including sheep [29],
pig [17] and cattle [22]. Cell cultures isolated by this
Figure 1 Cell surface markers and population doublings of
bMSC cultures isolated from fetal bone marrow. (A) Higher
(P < 0.001) levels of mRNA of MSC surface markers (CD73, CD90, and
CD105) were detected in comparison to hematopoietic surface
markers (CD34 and CD45) levels. (B) PD time (days) were no
significantly different among 7 consecutive culture passages.
Superscripts (*) represent significant (P < 0.001) differences between
MSC and hematopoietic surface markers.
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tion that includes a mixture of progenitor cells with
different degrees of commitment [30]. In our study, iso-
lated bMSC maintained different cell morphologies from
fibroblast-like, spindle-shaped cells to large flat cells.
Despite this heterogeneous conformation, the bMSC
cultures expressed high levels of mRNA of MSC specific
surface markers CD73, CD90 and CD105 and scarce
levels of hematopoietic cell surface markers CD33 and
CD45. A constant growth rate was detected in bMSC
cultures for 7 consecutive passages. Similarly, bMSC
collected from calves were reported to have constant
growth rates until passage 10, followed by progressive
reduction and culture senescence [23]. Reports in hu-
man adults MSC indicated that senescence begins at
passage 3 [24], which suggests differences in proliferative
potential according to developmental stage. Althoughthe pluripotent potential of bMSC after more than 4 to
5 passages was not analyzed in the present study, it has
been reported that bMSC collected from calves BM are
able to maintain osteogenic differentiation potential for
up to 15 passages [23].
The multipotent state and potential for multilineage dif-
ferentiation of bMSC was evaluated using quantitative and
qualitative analyses. Protocols used for differentiation of
MSC have been previously reported in the same and other
species [22,31]. Culture of bMSC during a 27-day period
under osteogenic conditions induced complex cell morph-
ology and extracellular matrix formation. OC mRNA levels
and ALPL activity increased in differentiating bMSC com-
pared to untreated controls. Osteogenesis was confirmed
at Day 27 of differentiation by immunolabeling of OC and
von Kossa staining of matrix mineralization. These results
indicate that constant exposure to osteogenic medium in-
duced a time-dependent osteogenesis in fetal bMSC. Previ-
ous studies reported similar osteogenic potential in bMSC
isolated from calf BM and umbilical cord blood [22,25].
MSC derived from adult BM were reported to have equiva-
lent osteogenic capacity in other species including horse
[32], sheep [33] and pig [18]. Our data suggest that fetal
bMSC bear comparable osteogenic potential to perinatal
and postnatal MSC; however, a more comprehensive study
is required in order to determine potential differences be-
tween ontological stages. CD73 is a membrane-bound
glycoprotein involved in both signal transduction and ecto-
5′-nucleotidase activity. Although CD73 is a key molecule
for defining MSC [5], its specific role in MSC remains un-
known. Recent studies have suggested that CD73 may be
involved in MSC osteogenic differentiation via adenosine
receptor (A2AAR and A2BAR) signaling [34]. In our study,
CD73 mRNA was detected in all stages of bMSC differen-
tiation; however, at day 24 of culture differentiated bMSC
expressed lower level of CD73 mRNA compared to un-
treated controls. Similar reduction in CD73 expression has
been reported after osteogenic differentiation in human
MSC [35] suggesting that this protein may be regulated
during osteogenic differentiation.
A dose-dependent experiment was performed to evaluate
the effect of ascorbic acid and FBS supplementation in the
osteogenic differentiation on bMSC. Ascorbic acid plays a
key role as a cofactor in the post-translational modification
of collagen molecules [36]. Various mesenchyme-derived
cell types including osteoblasts, adipocytes, chondrocytes
and odontoblasts increase collagen production and osteo-
genic potential after exposure to ascorbic acid [37]. In our
study, culture of bMSC with high concentration of ascor-
bic acid (0.1 mM) resulted in higher OC mRNA levels and
ALPL activity, and stronger mineralization of the matrix
compared to lower concentration (0.001 mM). Moreover,
NANOG mRNA levels were intensely down-regulated in
bMSC treated with the same concentration. Supplementation
Figure 2 Osteogenic differentiation of bMSC isolated from fetal bone marrow. (A) Complex cell-interactions and extracellular matrix
formation were observed in differentiating bMSC during a 27-Day culture period. (B) Higher (P < 0.05) levels of OC mRNA and ALPL activity were
detected in differentiated bMSC at Days 16, 24 and 27 compared to untreated controls. NANOG mRNA levels increased (P < 0.05) from days 16 to
27 in differentiated mMSC. (C) CD73 mRNA expression was upregulated in untreated bMSC at Day 24 of osteogenic culture. (D) Activity of ALPL
were higher (P < 0.05) in differentiated bMSC compared to control. (E) Osteogenesis was confirmed at Day 27 of culture by immunodetection of
OC and (F) von Kossa staining of the matrix. Phase contrast (PC), OC and merged with DAPI for control and differentiation bMSC. Data are shown
as mean ± standard errors. Superscripts (a,b,*) represent significant (P < 0.05) differences between treatment and sampling days. Bar scale: (A)
500 μm; (E) 20 μm; (F) 500 μm.
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Figure 3 Dose-dependent effect of the ascorbic acid and FBS supplementation during osteogenic differentiation of bMSC. (A) Culture
of bMSC under high concentrations of ascorbic acid (0.1 mM) in combination with 10% or 5% FBS resulted in higher (P < 0.05) OC mRNA and
lower NANOG mRNA expression compared to other treatments. (B) ALPL activity decreased (P < 0.05) when acid ascorbic was eliminated or
reduced to 0.001 mM. (C) von Kossa (VK) staining evidenced higher matrix mineralization in bMSC cultures supplemented with 0.1 mM ascorbic
acid in combination with 10 and 5% FBS. Data are shown as mean ± standard errors. Superscripts (a,b,*) represent significant (P < 0.05)
differences between treatment and sampling days. Bar scale: 500 μm.
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eration of MSC [38]. The effect of FBS alters the meta-
bolic state of MSC and may also affect the terminal
differentiation of MSC. In our study, reduction in FBS to
5% and 2% in bMSC culture media resulted in lower OC
mRNA levels and less mineralization of the matrix com-
pared to 10%. However, ALPL activity and NANOG
mRNA levels were not affected by these treatments.Overall, these results indicate that osteogenic differenti-
ation of bMSC may be enhanced by increasing ascorbic
acid supplementation to media culture; whereas; reduc-
tion in FBS supplementation to 5% or 2% may comprom-
ise the osteogenic differentiation process.
Culture of bMSC for 21 days under chondrogenic con-
ditions that included supplementation of TGFβ resulted in
formation of a cartilage pellet. Up-regulation of cartilage-
Figure 4 (See legend on next page.)
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Figure 4 Chondrogenic differentiation of bMSC isolated from fetal bone marrow. (A) Culture of bMSC under differentiation media during
21 days resulted in cartilage pellet formation. (a) bMSC were differentiated using micromass culture system (b) formed cartilage pellet after
21 days of culture. (c and d) Presence of glycosaminoglycans was confirmed in histological sections of the pellet by alcian blue staining. (B)
Levels of ACAN mRNA increased (P < 0.05) in differentiating bMSC at Days 7, 14 and 21compared to untreated controls. In contrast, lower (P <
0.05) levels of NANOG mRNA were detected in differentiating bMSC at Days 7 and 21compared to untreated controls. (C) COL2A1 and (D) SOX9
mRNA levels increased in differentiated bMSC at day 21 of culture. (E) ACAN was immunodetected in cartilage pellet at Day 21 of culture. Phase
contrast (PC), ACAN, and merged with DAPI for control (treated with non-immune serum instead of primary antibody) and differentiation bMSC.
Data are shown as mean ± standard errors. Superscripts (a,b,*) represent significant (P < 0.05) differences between treatment and sampling days.
Bar scale: (b) 2 mm; (c) 200 μm; (d) 100 μm; (C), 500 μm.
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chondrogenic differentiation of bMSC. Alcian blue stain-
ing of glycosaminoglycans in histological sections of the
cartilage pellet confirmed extracellular matrix formation.
Comparable results were previously reported in other
study using similar number of bMSC and concentration
of TGFβ [39]. However, these authors also described
spontaneous differentiation of bMSC cultured in TGFβ-
free media. In our study, bMSC cultured in control media
(high glucose DMEM) expressed low levels of ACAN,
COL2A1 and SOX9 mRNA and were unable to undergo
cartilage formation. Despite the effect of TGFβ was not
evaluated in our study, our data indicate that media
containing chondrogenic factors is required to induce dif-
ferentiation of bMSC.
Adipogenic differentiation of bMSC was first charac-
terized by observation of drastic morphology changes in-
cluding formation of cell aggregates and accumulation of
lipid vacuoles. Levels of PPARγ mRNA in bMSC during
adipogenesis were no significantly different between treat-
ments. At Day 18 of adipogenic culture, mRNA levels of
PPARγ were 2.5-fold higher in differentiated compared to
control bMSC. These results differ from a previous study
using bMSC isolated from 2-to-6 months old calves, where
PPARγ mRNA levels were 8.4-fold higher in differentiated
compared to control cells [22]. Differences in results
between both studies may be associated to the limited de-
velopmental activation of the PPARγ gene in fetal com-
pared to calf bMSC, since preadipocyte differentiation and
number of PPARγ positive cells have a dependent associ-
ation with fetal age [40]. Despite reduced levels of PPARγ
mRNA, the PPARγ protein was immunodetected in the
nuclei of differentiated bMSC at Day 18 of culture. Nuclear
localization follows PPARγ activation in various types of
cells indicating that a functional PPARγ protein is present
in differentiated bMSC [41,42]. The absence of PPARγ sig-
nal in the control bMSC at the same stage may be the con-
sequence of the reduced levels of PPARγ mRNA detected
in these cells, which were similar to the undifferentiated
state at Day 0 of culture (0.73-fold expression of the undif-
ferentiated bMSC). In contrast to PPARγ, levels of AP2
mRNA were up-regulated at Days 12 and 18 of culture in
differentiated bMSC compared to controls. Adipogenesis
was confirmed at Day 18 of culture by detection of lipidvacuoles using oil red staining. Overall these results indi-
cate that bMSC from fetal BM conserve adipogenic poten-
tial under in vitro culture conditions; however, these cells
may also present variations in the expression of some
adipogenic markers described in postnatal MSC.
The levels of NANOG and OCT4 mRNA were ana-
lyzed with the aim to evaluate the state of multipotency
in bMSC during mesenchymal differentiation. NANOG
and OCT4 regulate the maintenance of pluripotent state
in embryos and derived cells in most mammalian species
[43,44]. Both transcription factors had been proposed to
play a similar role in adult stem cells [45]. However,
recent reports have questioned this role under in vitro
conditions [46]. Our analyses by Q-PCR using two differ-
ent sets of primers were unable to detect OCT4 mRNA
both in undifferentiated and differentiated bMSC (data
not shown). The lack of OCT4 expression has also been
reported in MSC derived from human BM [13]. In our
study, the pattern of NANOG mRNA changed according
to lineage differentiation. While NANOG mRNA levels
were not affected under adipogenic culture; the osteo-
genic and chondrogenic conditions induced higher and
lower expression of this gene, respectively. These results
agree with data in human MSC where expression of
NANOG was associated to adaptation to in vitro cell
growth conditions [13]. Moreover, these results suggest
that NANOG expression is significantly affected by cul-
ture conditions of bMSC.
Conclusions
Our data generated by quantitative and qualitative ana-
lyses support the capacity for multilineage differentiation
of bone marrow MSC isolated from abattoir-derived bo-
vine fetuses. The expression patterns of linage-specific
markers in differentiating bMSC were similar to previ-
ously reported for bMSC derived from other sources.
However, expression patterns of pluripotent markers
mRNA OCT4 and NANOG were different from previously
reported in other species, suggesting that variation may
occur according to animal species or culture conditions.
The osteogenic differentiation of bMSC was affected by
ascorbic acid and FBS concentrations in culture media.
The simplicity of isolation and the potential to differenti-
ate into several cell types lays the foundation for bone
Figure 5 (See legend on next page.)
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Figure 5 Adipogenic differentiation of bMSC isolated from fetal bone marrow. (A) Culture of bMSC under adipogenic conditions induced
drastic morphology changes including formation of cell aggregates and accumulation of lipid vacuoles in the cytoplasm. (B) AP2 mRNA levels
increased (P < 0.05) in differentiating bMSC at Days 12 and 18 of culture. (C) In contrast, expression levels of PPARγ mRNA were similar between
treatments. (D) PPARγ was immunodetected in differentiated bMSC but not in controls at Day 18 of culture. (E) Adipogenesis was confirmed by
oil red (OR) staining of lipids vacuoles in differentiated bMSC at Day 18 of culture. Phase contrast, PPARγ and merged with DAPI for control and
differentiation bMSC. Superscripts (a,b,*) represent significant (P < 0.05) differences between treatment and sampling days. Bar scale: (A) 500 μm;
(D) 20 μm; (E) 500 μm.
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tuses, as an alternative source of MSC for investigation of
biology and eventual applications for regenerative therapy
in human and veterinary medicine.
Methods
All procedures have been approved by the Bioethical
Committee of the National Commission for Scientific
and Technology Research (Fondecyt).
Isolation and culture of bMSC from fetal bone marrow
Bone marrow was aspirated from bovine fetuses (n = 10;
7–8 months of gestation) collected at a local abattoir.
The marrow was drawn from femoral marrow cavity into
syringes containing high glucose Dulbecco’s Modified
Eagle Medium (DMEM, Gibco, Grand Islands, NY, USA)
supplemented with 10% fetal bovine serum (FBS), 1000 U
heparin, 100 U/ ml penicillin and 100 μg/ml streptomycin.
Bone marrow samples were washed twice with phosphate-
buffered saline (PBS) and twice with DMEM. Then cells
were plated in DMEM (high glucose) supplemented with
10% FBS, 100 U/ml penicillin, 100 μg/ml streptomycin
and 0.25 μg/ml amphotericin B. Cells were incubated at
38°C in a humidified atmosphere containing 5% CO2.
Non-adherent cells were removed by changing the culture
medium after 2 days. Following the initial 2 days, the
medium was changed every 2–3 days. After 4 to 5 pas-
sages, cells were gently harvested when 90% confluent
using 0.25% trypsin in 0.1% EDTA. Thereafter, cell num-
ber was determined at all consecutive passages and time
of population doubling was calculated until culture pas-
sage 7. Following determination of cell viability, cells were
used to initiate differentiation experiments.
Osteogenic differentiation
Cells (5×104/cm2) isolated from 3 fetuses were plated in T-
25 culture dishes either in control (three replicates) or
differentiation (three replicates) medium and cultured as
described above for a 27-Day experiment. Control medium
consisted of DMEM (high glucose) supplemented with 10%
FBS, 100 U/ml penicillin, 100 μg/ml streptomycin and
0.25 μg/ml amphotericin B. Differentiation medium con-
sisted of control medium supplemented with 100 nM dexa-
methasone, 10 mM sodium β-glycerophosphate, 0.05 mM
ascorbic acid (all from Sigma-Aldrich, St. Louis, MO,USA). Cells were cultured for 24 days, with the medium be-
ing changed every 2 days. On Day 24, 10 nM of 1, 25-
dihydroxyvitamin D3 (Vitamin D, Sigma) was added to
differentiation medium until Day 27 of culture. Samples
were obtained at Days 0, 8, 16, 24 and 27 and analyzed for
GAPDH, β-ACTIN, OC, OCT4 and NANOG expression by
Q-PCR. The level of osteogenic differentiation was also an-
alyzed at Day 27 of differentiation by immunodetection of
OC protein, quantification of ALP activity and visualization
of von Kossa staining of mineralized materials in the cell
culture. In order to analyze the effect of various concentra-
tions of ascorbic acid (0, 0.1, 0.01, and 0.001 mM) and FBS
(0, 1, 5, and 10%) on bMSC osteogenic differentiation, cells
were cultured under the same conditions described previ-
ously. The osteogenic differentiation in MSC was evaluated
on Days 0 and 27 using the analyses described above.
Chondrogenic differentiation
Cells (1×106) isolated from 3 fetuses were resuspended
into 1 ml of control (three replicates) or differentiation
(three replicates) medium, transferred into 15-ml tubes
and centrifuged at 500 g for 5 min. Control medium
consisted of DMEM (high glucose) supplemented with
100 U/ml penicillin, 100 μg/ml streptomycin and 0.25 μg/
ml amphotericin B. Differentiation medium consisted in
control medium supplemented with 10% ITS (6.25 μg/ml
insulin, 6.25 μg/ml transferrin, 6.25 μg/ mL selenious
acid), 1 mM pyruvate, 50 μg/ml ascorbate 2-phosphate,
0.1 μM dexamethasone, and 8 ng/ml TGFβ1 (R&D Sys-
tems, MN, USA). Pellets were cultured for 21 days under
38°C in a humidified atmosphere containing 5% CO2.
Samples were obtained at seven-day intervals for a total of
21 days and analyzed for GAPDH, β-ACTIN, ACAN,
COL2A1, SOX9, OCT4 and NANOG expression by Q-
PCR. The level of chondrogenic differentiation was also
analyzed at Day 21 of differentiation by immunodetection
of ACAN protein and visualization of glycosaminoglycan
formation using alcian blue staining in micromass histo-
logical sections.
Adipogenic differentiation
Cells (2–5 7× 103/cm2) isolated from 3 fetuses were seeded
in control (three replicates) or differentiation (three repli-
cates) medium. Control medium consisted of DMEM (high
glucose) supplemented with 10% FBS, 100 U/ml penicillin,
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Differentiation medium consisted in control medium sup-
plemented with 10% FBS, 1 μM dexamethasone, 0.5 mM
indomethacin, 10 μg/ml insulin and 100 mM 3-isobutyl-1-
methylxanthine (all from Sigma). Cells were cultured in
differentiation medium for 3 days and then in dif-
ferentiation maintenance medium containing DMEM
(high glucose), 10% FBS and 10 μg/ml insulin for 3 add-
itional days in a total experimental period of 18 days. Sam-
ples were obtained at six-day intervals for 18 days and
analyzed for GAPDH, β-ACTIN, PPARγ, AP2, OCT4 and
NANOG expression by Q-PCR. The level of adipogenic dif-
ferentiation was also analyzed at Day 18 of differentiation
by immunodetection of PPARγ protein and visualization of
fat aggregates in cultured cells using Oil Red staining.RNA Extraction and cDNA synthesis
Approximately 3 × 105 MSC were collected and immedi-
ately fixed in RLT buffer (Qiagen, Incorporated, Valencia,
CA). Total RNA was extracted using RNeasy Mini kit
(Qiagen) according to the manufacturing’s instructions.
The concentration and purity of the RNA in each sample
were determined using spectrophotometry (BioRad La-
boratories, Hercules, CA, USA). Total RNA was eluted in
30–50 μl of RNase free water. Samples were subjected to
RT-PCR using a Brilliant II SYBR Green RT-PCR kit
(Agilent Technologies, Santa Clara, CA, USA). The reac-
tion protocol consisted of incubation for 5 min at 25°C,
15 min at 42°C, 5 min at 95°C and hold at 4°C using a
DNA engine PCR thermocycler (Bio-Rad).Quantitative-PCR
Real-time PCR primers were designed using PrimerExpress
software (Applied Biosystems Incorporated, Foster City,
CA) (Table 1). Equivalence of amplification efficiencies
among all primer-probe sets was confirmed using serial 3-
fold dilutions of differentiated MSC cDNA. Each RT-PCR
reaction (25 μl) contained the following: 2X Brilliant II
SYBR Green QPCR master mix (12.5 μl), diluted reference
dye (0.375 μl), target forward primer (200 nM), target
reverse primer (200 nM), cDNA synthesis reaction
(2 μl) and nuclease-free PCR-grade water to adjust final
volume. The PCR amplification was carried out in
StepOne Real Time PCR System (Applied Biosystems).
Thermal cycling conditions were 95°C for 10 min,
followed by 40 repetitive cycles at 95°C for 30 sec and
60°C for 1 min. As a normalization control for RNA
loading, parallel reactions in the same multiwell plate
were performed using glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) or β-ACTIN as a target. Quanti-
fication of gene amplification was made following
Q-PCR by determining the threshold cycle (CT) number
for SYBR fluorescence within the geometric region ofthe semilog plot generated during PCR. Within this re-
gion of the amplification curve, each difference of one
cycle is equivalent to a doubling of the amplified prod-
uct of the PCR. The relative quantification of the target
gene expression across treatment was evaluated using
the comparative ΔΔCT method. The CT value was deter-
mined by subtracting the most stable endogenous gene
CT value (GAPDH, osteogenesis and chondrogenesis; β-
ACTIN, adipogenesis) from the target CT value of the
sample. Calculation of ΔΔ CT involved using target gene
expression on Day 0 (sample with the highest CT value
or lowest target expression) as an arbitrary constant to
subtract from all other CT sample values. Relative target
mRNA expression for differentiation markers was calcu-
lated as fold changes in relation to Day 0 sample and
expressed as 2-ΔΔCT value. Relative mRNA expression for
cell surface markers was calculated as fold changes in rela-
tion to CD34 mRNA levels and expressed as 2-ΔΔCT value.
Immunofluorescence
Differentiated MSC were cultured in 35-mm dishes, fixed
in a 4% paraformaldehyde (PAF) for 10 min and stored at
4°C under PBS. Cells were then washed twice in PBS twice
and blocked in donkey serum (Sigma-Aldrich) for 30 min
at RT. Cells were incubated over-night at 4°C with pri-
mary mouse monoclonal (OC) or goat polyclonal (ACAN
or PPARγ) antibodies (1:50; Santa Cruz Biotechnology,
Santa Cruz, CA, USA) diluted in donkey serum. After
three washes with PBS, cells were incubated with goat
anti-mouse or anti-goat IgG conjugated to FITC (1:200 in
donkey serum). Then cells were again washed three times
in PBS and mounted under coverslips in a solution
containing 4′, 6-diamidino-2-phenylindole (Santa Cruz
Biotechnology). Samples were examined under epifluores-
cence and the results captured by digital photomicroscopy
(Olympus, Tokyo, Japan).
Cartilage pellet preparations obtained from chondrogenic
differentiation were fixed in 4% PAF for 20 min and stored
in PBS at 4°C until processing. Pellet preparations were
pre-embedded in 4% agar (Bacto-agar, Difco Lab, Detroit,
MI) under a stereomicroscope. Specimens were trimmed,
embedded in paraffin and sectioned at 5–7 μm using a
microtome. Tissue sections were mounted on adhesive
slides (Newcomer Supply, Middleton, WI) and incubated
overnight at 37°C. Mounted tissues were deparaffinized in
xylene and rehydrated in serial alcohol solutions. Tissue
sections were then rinsed two times in 0.1 M PBS (pH 7.4)
and blocked in 2.5% donkey serum for 15 min. ACAN was
specifically detected by overnight incubation at room
temperature with primary antibody (1:50) diluted in 1.5%
donkey serum solution (Santa Cruz Biotechnology). After
two washes in 0.1 M PBS (pH 7.4), bound primary antibody
was detected goat anti-mouse IgG conjugated to FITC
(1:200 in donkey serum). Then cells were again washed
Table 1 Sequence of primers used for Q-PCR analysis
Gene Sense Antisense Accession number
GAPDH 5′ CCTTCATTGACCTTCACTACATGGTCTA 5′ TGGAAGATGGTGATGGCCTTTCCATTG NM 001034034.2
βACTIN 5′CGCACCACTGGCATTGTCAT 5′TCCAAGGCGACGTAGCAGAG K00622.1
CD34 5′TGGGCATCGAGGACATCTCT 5′GATCAAGATGGCCAGCAGGAT AB021662
CD45 5′CCTGGACACCACCTCAAAGCT 5′TCCGTCCTGGGTTTTATCCTG NM 001206523
CD73 5′TGGTCCAGGCCTATGCTTTTG 5′GGGATGCTGCTGTTGAGAAGAA BC114093
CD90 5′CAGAATACAGCTCCCGAACCAA CACGTGTAGATCCCCTCATCCTT BC104530
CD105 5′CGGACAGTGACCGTGAAGTTG 5′TGTTGTGGTTGGCCTCGATTA NM 001076397
OC 5′ TGACAGACACACCATGAGAACCC 5′ AGCTCTAGACTGGGCCGTAGAAG EF673278.1
CD73 5′AATGGCACGATTACCTGGGA 5′GGGAGGATCACCTTGTACAC BT026240.1
ACAN 5′ CACTGTTACCGCCACTTCCC 5′ GACATCGTTCCACTCGCCCT NM 173981.2
COL2A1 5′ ATCCATTGCAAACCCAAAGG 5′ GACATCGTTCCACTCGCCCT NM 001113224.1
SOX9 5′CATGAAGATGACCGACGAG 5′ CGTCTTCTCCGTGTCGGA AF278703.1
AP2 5′ CTGGCATGGCCAAACCCA 5′ GTACTTGTACCAGAGCACC NM 174314.2
PPARγ 5′ CGCACTGGAATTAGATGACAGC 5′ CACAATCTGTCTGAGGTCTGTC BC116098.1
NANOG 5′ GTGTTTGGTGAACTCTCCTG 5′ GGGAATTGAAATACTTGACAG NM 001025344.1
OCT4 (1) 5′ ACACTCGGACCACGTCTTTC 5′ CGCATGGGTACCAGTGCACCTT AF022987
OCT4 (2) 5′ GTTCTCTTTGGAAAGGTGTTC 5′ ACACTCGGACCACGTCTTTC AY490804.1
(1) and (2) represents sets of primers used for OCT4 mRNA amplification.
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tion containing 4′, 6-diamidino-2-phenylindole (Santa Cruz
Biotechnology) for nuclei visualization. Samples were ex-
amined under epifluorescence and the results captured by
digital photomicroscopy (Olympus, Tokyo, Japan). Neigh-
boring sections were used for the following experimental
controls: 1) positive control using cartilaginous tissue, 2) re-
placement of the primary antibody with non-immune
serum, 3) omission of primary and secondary antibody.
Alkaline phosphatase
Activity of ALPL was detected in bMSC cultured under
different osteogenic conditions after day 27 of culture using
a Calbiochem kit (EMD Biosciences, CA, USA). Each ana-
lysis included a positive control (ALP) and a negative con-
trol (triton). bMSC were permeabilized using 0.2% triton
for 20 min at 38°. Each reaction contained 50 μl of cell lys-
ate, 100 μl of ALP substrate (p-NPP), 40 μl p-NPP concen-
trate, 1560 μl of dH2O and 400 μl of p-NPP buffer.
Reaction tubes were analyzed at 1, 20, 25 and 30 min
under 415 nm of absorbance using a spectrophotometer.
von Kossa staining
Mineral deposits in differentiated and control CMM at
day 27 of culture were detected using von Kossa stain-
ing. bMSC cultured in T-25 dishes were incubated with
5% solution of AgNO3 under darkness. Then cells were
washed with distilled water (dH2O) and exposed to light.
Cells were counterstained after incubation with 2% saf-
ranin solution for 3 min. Samples were examined underbright field microscope and the results captured by
digital photomicroscopy (Olympus, Tokyo, Japan).
Alcian blue staining
Cartilage pellets were fixed with 10% PAF for 2 h and then
stored in PBS at 4°C until processed. Then pellets were par-
affin embedded, sectioned at 5 μm sections and mounted
on glass slides. Sagittal sections were deparaffinized, rehy-
drated in serial alcohol solutions and incubated in 0.5%
alcian blue staining for 10 min. Samples were examined
under bright field microscope and the results captured by
digital photomicroscopy (Olympus, Tokyo, Japan).
Oil red staining
Lipid vacuoles were detected in differentiated and controls
bMSC after 18 days of adipogenic differentiation using oil
Red staining. bMSC were fixed with 4% PAF for 1 h. Then
cells were incubated in 0.2% oil red for 2 h, washed with
dH2O and counterstained with hematoxylin. Samples were
examined under bright field microscope and the results cap-
tured by digital photomicroscopy (Olympus, Tokyo, Japan).
Data analysis
Values of gene expression from three different replicates
were transferred to a spreadsheet and then analyzed using
Infostat (version 2008). Data was normalized to logarith-
mic scale in base 10 for normality and mean values for
each replicate were compared by one-way ANOVA. Gene
expression values for each day of culture and cell surface
markers, and PD values were compared using Dunnet test.
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Duncan’s multiple comparison test.
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